Flamel Technologies S.A. (FLML) Monday said it has received a Prescription Drug User Fee Act date of August 6, 2014 from the U.S. Food and Drug Administration or FDA , for its second New Drug Application or NDA for an Unapproved Marketed Drug.
Earlier, the company had received a Complete Response Letter to its NDA on April 28. After re-submission of NDA on June 6, FDA classified the CRL resubmission as a Class 1 response.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.